Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
L01EX08
|
| gptkbp:CASNumber |
170364-57-1
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2023)
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:hasInChIKey |
QJQYQKZDHGJZKJ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C27H26N6O
|
| gptkbp:hasSMILES |
CN1CCN(CC1)C2CCN(C2)C3=CC=C(C=C3)C(=O)NC4=NC=CC(=C4)C5=CN(C6=CC=CC=C56)C
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
enzastaurin
|
| gptkbp:intendedUse |
anticancer agent
|
| gptkbp:IUPACName |
4-[(3S)-3-(4-methylpiperazin-1-yl)pyrrolidin-1-yl]-N-[4-(1-methylindol-3-yl)pyridin-2-yl]benzamide
|
| gptkbp:legalStatus |
investigational
|
| gptkbp:mechanismOfAction |
protein kinase C beta inhibitor
|
| gptkbp:molecularWeight |
450.5 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201737
9941576 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
LY317615
|
| gptkbp:target |
VEGF pathway
protein kinase C beta |
| gptkbp:bfsParent |
gptkb:PKC_beta
gptkb:PKC_theta gptkb:staurosporine |
| gptkbp:bfsLayer |
7
|